Limited data from small test trial shows positive results against South Africa and Brazil strains
The first “tweaked” vaccine against the worrying coronavirus variants that emerged in South Africa and Brazil has successfully neutralised them in laboratory trials, the US company Moderna has said.
The results of the small trial suggest that boosters against the variants will be feasible and could be rolled out this year to counter the threat from variants that have appeared around the world and are feared in some cases to be more transmissible or partially vaccine-resistant.